GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shockwave Medical Inc (NAS:SWAV) » Definitions » EBIT

Shockwave Medical (Shockwave Medical) EBIT : $192.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shockwave Medical EBIT?

Shockwave Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $52.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $192.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shockwave Medical's annualized ROC % for the quarter that ended in Mar. 2024 was 34.61%. Shockwave Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 84.06%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shockwave Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.57%.


Shockwave Medical EBIT Historical Data

The historical data trend for Shockwave Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shockwave Medical EBIT Chart

Shockwave Medical Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -50.10 -64.41 -7.74 122.71 181.19

Shockwave Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.37 33.81 47.59 58.41 52.94

Competitive Comparison of Shockwave Medical's EBIT

For the Medical Devices subindustry, Shockwave Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shockwave Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shockwave Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shockwave Medical's EV-to-EBIT falls into.



Shockwave Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $192.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shockwave Medical  (NAS:SWAV) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shockwave Medical's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=169.628 * ( 1 - -10.69% )/( (525.151 + 559.909)/ 2 )
=187.7612332/542.53
=34.61 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1566.563 - 50.858 - ( 990.554 - max(0, 104.205 - 1225.26+990.554))
=525.151

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1643.747 - 54.605 - ( 1029.233 - max(0, 92.334 - 1275.35+1029.233))
=559.909

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Shockwave Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=211.768/( ( (98.63 + max(134.142, 0)) + (113.612 + max(157.436, 0)) )/ 2 )
=211.768/( ( 232.772 + 271.048 )/ 2 )
=211.768/251.91
=84.06 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(114.552 + 107.587 + 12.567) - (50.858 + 0 + 49.706)
=134.142

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(124.44 + 111.215 + 10.462) - (54.605 + 0 + 34.076)
=157.436

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shockwave Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=192.755/12315.267
=1.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shockwave Medical EBIT Related Terms

Thank you for viewing the detailed overview of Shockwave Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Shockwave Medical (Shockwave Medical) Business Description

Traded in Other Exchanges
Address
5403 Betsy Ross Drive, Santa Clara, CA, USA, 95054
ShockWave Medical Inc is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States, Europe and other countries.
Executives
Douglas Evan Godshall director, officer: President & CEO SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Frank T Watkins director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Isaac Zacharias officer: Chief Commercial Officer 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Dan Puckett officer: CFO & Secretary 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Trinh Phung officer: VP, Finance C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Laura Francis director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Sara Toyloy director C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Kevin J. Ballinger director C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Antoine Papiernik director, 10 percent owner 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Sofinnova Capital Vii Fcpr 10 percent owner C/O SOFINNOVA PARTNERS, 18 RUE DU 4 SEPTEMBRE, 75002 PARIS I0 00000
Cahill Colin director 5403 BETSY ROSS DRIVE, SANTA CLARA CA 95054
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Larkin C Raymond Jr director C/O MALLINCKRODT INC, 7733 FORSYTH BLVD, ST LOUIS MO 63105